Merck and Quotient Strike IBD Deal
March 24, 2026
Merck has signed a $20 million deal with Quotient in inflammatory bowel disease, adding another targeted biotech business development transaction to March.
March 24, 2026
Merck has signed a $20 million deal with Quotient in inflammatory bowel disease, adding another targeted biotech business development transaction to March.